Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Eloxx Pharmaceuticals, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- −6 vs. Q2 2021
- Shares held
- 16.1M
- −563.6K (−3.4%) vs. Q2 2021
- Total value
- $26.0M
- −$7.14M (−21.5%) vs. Q2 2021
- New holders
- 8
- 12 more added
- Sold out
- 14
- 12 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELOX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $34.7M |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $0 |
| Q2 2024 | 1 | $43 |
| Q1 2024 | 1 | $62 |
| Q4 2023 | 4 | $109.0K |
| Q3 2023 | 18 | $2.50M |
| Q2 2023 | 16 | $924.2K |
| Q1 2023 | 19 | $671.5K |
| Q4 2022 | 19 | $476.7K |
| Q3 2022 | 32 | $2.14M |
| Q2 2022 | 32 | $3.51M |
| Q1 2022 | 36 | $8.42M |
| Q4 2021 | 39 | $11.7M |
| Q3 2021 | 41 | $26.0M |
| Q2 2021 | 47 | $33.2M |
| Q1 2021 | 38 | $28.7M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Eloxx Pharmaceuticals, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 41 | $0 | 0.00% | −1,272−96.9% | Reduced |
| Brewin Dolphin Ltd | 15 | $24 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 793 | $1.00K | 0.00% | −19,368−96.1% | Reduced |
| FMR LLC | 338 | $1.00K | 0.00% | +338 | New |
| BNP Paribas Arbitrage, SA | 722 | $1.18K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 3,678 | $6.00K | 0.00% | −2,775−43.0% | Reduced |
| Bank of America Corp | 6,077 | $9.00K | 0.00% | +5,141+549.3% | Added |
| Victory Capital Management Inc | 11,120 | $18.0K | 0.00% | −1,239−10.0% | Reduced |
| Advisor Group Holdings, Inc. | 12,359 | $20.0K | 0.00% | 00.0% | Unchanged |
| Sawtooth Solutions, LLC | 16,201 | $26.0K | 0.00% | +16,201 | New |
| Mesirow Financial Investment Management, Inc. | 18,894 | $31.0K | 0.09% | 00.0% | Unchanged |
| ExodusPoint Capital Management, LP | 19,720 | $32.0K | 0.00% | +19,720 | New |
| Wells Fargo & Company | 21,370 | $36.0K | 0.00% | −85−0.4% | Reduced |
| Price T Rowe Associates Inc | 22,700 | $37.0K | 0.00% | +22,700 | New |
| Meeder Asset Management Inc | 25,778 | $41.0K | 0.00% | +5,321+26.0% | Added |
| Goldman Sachs Group Inc | 27,588 | $45.0K | 0.00% | +27,588 | New |
| Private Advisor Group, LLC | 32,510 | $52.0K | 0.00% | +32,510 | New |
| Occudo Quantitative Strategies LP | 41,642 | $68.0K | 0.01% | −605−1.4% | Reduced |
| Susquehanna International Group, LLP | 45,044 | $73.0K | 0.00% | +14,282+46.4% | Added |
| D. E. Shaw & Co., Inc. | 63,698 | $104.0K | 0.00% | +63,698 | New |
| Bank of New York Mellon Corp | 76,122 | $124.0K | 0.00% | +64,183+537.6% | Added |
| Bridgeway Capital Management, LLC | 91,400 | $149.0K | 0.00% | −57,600−38.7% | Reduced |
| Citadel Advisors LLC | 104,288 | $170.0K | 0.00% | +2,628+2.6% | Added |
| Natixis | 103,900 | $170.0K | 0.00% | +103,900 | New |
| Simplex Trading, LLC | 95,702 | $191.0K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 124,369 | $202.0K | 0.00% | −12,503−9.1% | Reduced |
| State Street Corp | 194,403 | $317.0K | 0.00% | +5,200+2.7% | Added |
| Millennium Management LLC | 274,297 | $447.0K | 0.00% | −119,406−30.3% | Reduced |
| Vanguard Capital Wealth Advisors | 437,900 | $457.0K | 0.35% | +312,900+250.3% | Added |
| Two Sigma Investments, LP | 314,874 | $513.0K | 0.00% | +208,374+195.7% | Added |
| BlackRock Inc. | 490,871 | $800.0K | 0.00% | +300,153+157.4% | Added |
| Clal Insurance Enterprises Holdings Ltd | 585,000 | $954.0K | 0.01% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 705,300 | $1.15M | 0.00% | +480,800+214.2% | Added |
| Geode Capital Management, LLC | 772,836 | $1.26M | 0.00% | +245,529+46.6% | Added |
| Altium Capital Management LP | 1,118,000 | $1.82M | 0.49% | +447,882+66.8% | Added |
| Altshuler Shaham Ltd | 1,157,540 | $1.90M | 0.01% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 1,209,338 | $1.97M | 0.12% | −1,056,949−46.6% | Reduced |
| Silverarc Capital Management, LLC | 1,259,840 | $2.05M | 1.19% | −627,699−33.3% | Reduced |
| American Financial Group Inc | 1,480,000 | $2.41M | 0.64% | 00.0% | Unchanged |
| Menora Mivtachim Holdings Ltd. | 2,094,208 | $3.41M | 0.05% | 00.0% | Unchanged |
| Vanguard Group Inc | 3,047,038 | $4.97M | 0.00% | −8,479−0.3% | Reduced |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −367,062−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −163,900−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −121,900−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −83,344−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −74,056−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −68,000−100.0% | Sold out |
| Gratia Capital, LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −46,884−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −14,435−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −12,034−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −11,635−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −10,612−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,587−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −228−100.0% | Sold out |